nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetylsalicylic acid—TP53—liver cancer	0.563	0.851	CbGaD
Acetylsalicylic acid—ALB—liver cancer	0.0981	0.148	CbGaD
Acetylsalicylic acid—CYP2C8—Sorafenib—liver cancer	0.0165	0.276	CbGbCtD
Acetylsalicylic acid—CYP2C19—Sorafenib—liver cancer	0.0138	0.232	CbGbCtD
Acetylsalicylic acid—CYP2C9—Sorafenib—liver cancer	0.0115	0.192	CbGbCtD
Acetylsalicylic acid—ABCB1—Sorafenib—liver cancer	0.0112	0.187	CbGbCtD
Acetylsalicylic acid—ABCB1—Doxorubicin—liver cancer	0.00677	0.113	CbGbCtD
Acetylsalicylic acid—TP53—gall bladder—liver cancer	0.00511	0.136	CbGeAlD
Acetylsalicylic acid—NFKBIA—gall bladder—liver cancer	0.00503	0.133	CbGeAlD
Acetylsalicylic acid—TP53—embryo—liver cancer	0.00324	0.086	CbGeAlD
Acetylsalicylic acid—NFKBIA—embryo—liver cancer	0.00319	0.0846	CbGeAlD
Acetylsalicylic acid—HSPA5—embryo—liver cancer	0.00312	0.0829	CbGeAlD
Acetylsalicylic acid—RPS6KA3—embryo—liver cancer	0.00266	0.0706	CbGeAlD
Acetylsalicylic acid—IKBKB—embryo—liver cancer	0.00196	0.0521	CbGeAlD
Acetylsalicylic acid—ALB—gall bladder—liver cancer	0.00181	0.048	CbGeAlD
Acetylsalicylic acid—TP53—liver—liver cancer	0.0015	0.0398	CbGeAlD
Acetylsalicylic acid—NFKBIA—liver—liver cancer	0.00148	0.0391	CbGeAlD
Acetylsalicylic acid—HSPA5—liver—liver cancer	0.00144	0.0383	CbGeAlD
Acetylsalicylic acid—RPS6KA3—liver—liver cancer	0.00123	0.0326	CbGeAlD
Acetylsalicylic acid—PTGS2—gall bladder—liver cancer	0.000985	0.0261	CbGeAlD
Acetylsalicylic acid—IKBKB—liver—liver cancer	0.000908	0.0241	CbGeAlD
Acetylsalicylic acid—SLC22A7—liver—liver cancer	0.000881	0.0234	CbGeAlD
Acetylsalicylic acid—NFKBIA—Doxorubicin—Epirubicin—liver cancer	0.000846	0.173	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Daunorubicin—Epirubicin—liver cancer	0.000846	0.173	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Idarubicin—Epirubicin—liver cancer	0.000846	0.173	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Idarubicin—Doxorubicin—liver cancer	0.000782	0.16	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Daunorubicin—Doxorubicin—liver cancer	0.000782	0.16	CbGdCrCtD
Acetylsalicylic acid—NFKBIA—Epirubicin—Doxorubicin—liver cancer	0.000782	0.16	CbGdCrCtD
Acetylsalicylic acid—PTGS2—embryo—liver cancer	0.000625	0.0166	CbGeAlD
Acetylsalicylic acid—Kidney function abnormal—Epirubicin—liver cancer	0.000549	0.0262	CcSEcCtD
Acetylsalicylic acid—ALB—liver—liver cancer	0.00053	0.0141	CbGeAlD
Acetylsalicylic acid—Kidney function abnormal—Doxorubicin—liver cancer	0.000508	0.0243	CcSEcCtD
Acetylsalicylic acid—Hypokalaemia—Sorafenib—liver cancer	0.000474	0.0227	CcSEcCtD
Acetylsalicylic acid—Eruption—Epirubicin—liver cancer	0.000431	0.0206	CcSEcCtD
Acetylsalicylic acid—CYP2C19—liver—liver cancer	0.000427	0.0113	CbGeAlD
Acetylsalicylic acid—Eruption—Doxorubicin—liver cancer	0.000399	0.0191	CcSEcCtD
Acetylsalicylic acid—ABCB1—embryo—liver cancer	0.000386	0.0102	CbGeAlD
Acetylsalicylic acid—Haematemesis—Epirubicin—liver cancer	0.000382	0.0183	CcSEcCtD
Acetylsalicylic acid—CYP2C8—liver—liver cancer	0.000373	0.00989	CbGeAlD
Acetylsalicylic acid—Haemoglobin—Sorafenib—liver cancer	0.000362	0.0173	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Sorafenib—liver cancer	0.00036	0.0172	CcSEcCtD
Acetylsalicylic acid—Haematemesis—Doxorubicin—liver cancer	0.000353	0.0169	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Sorafenib—liver cancer	0.000336	0.0161	CcSEcCtD
Acetylsalicylic acid—Flushing—Sorafenib—liver cancer	0.000334	0.016	CcSEcCtD
Acetylsalicylic acid—CYP2C9—liver—liver cancer	0.000331	0.00878	CbGeAlD
Acetylsalicylic acid—Anaemia—Sorafenib—liver cancer	0.00029	0.0139	CcSEcCtD
Acetylsalicylic acid—PTGS2—liver—liver cancer	0.000289	0.00766	CbGeAlD
Acetylsalicylic acid—Angioedema—Sorafenib—liver cancer	0.000287	0.0137	CcSEcCtD
Acetylsalicylic acid—Syncope—Sorafenib—liver cancer	0.000281	0.0135	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Sorafenib—liver cancer	0.000281	0.0134	CcSEcCtD
Acetylsalicylic acid—Ulcer—Epirubicin—liver cancer	0.00028	0.0134	CcSEcCtD
Acetylsalicylic acid—Loss of consciousness—Sorafenib—liver cancer	0.000276	0.0132	CcSEcCtD
Acetylsalicylic acid—Hypertension—Sorafenib—liver cancer	0.000271	0.013	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Sorafenib—liver cancer	0.000267	0.0128	CcSEcCtD
Acetylsalicylic acid—Hepatocellular injury—Epirubicin—liver cancer	0.000265	0.0127	CcSEcCtD
Acetylsalicylic acid—Ulcer—Doxorubicin—liver cancer	0.000259	0.0124	CcSEcCtD
Acetylsalicylic acid—Melaena—Epirubicin—liver cancer	0.000259	0.0124	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Sorafenib—liver cancer	0.000256	0.0122	CcSEcCtD
Acetylsalicylic acid—Shock—Sorafenib—liver cancer	0.000252	0.012	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Sorafenib—liver cancer	0.000251	0.012	CcSEcCtD
Acetylsalicylic acid—Hepatocellular injury—Doxorubicin—liver cancer	0.000245	0.0117	CcSEcCtD
Acetylsalicylic acid—Coma—Epirubicin—liver cancer	0.000242	0.0116	CcSEcCtD
Acetylsalicylic acid—Melaena—Doxorubicin—liver cancer	0.00024	0.0115	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Sorafenib—liver cancer	0.000228	0.0109	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Sorafenib—liver cancer	0.000225	0.0108	CcSEcCtD
Acetylsalicylic acid—Coma—Doxorubicin—liver cancer	0.000224	0.0107	CcSEcCtD
Acetylsalicylic acid—Diabetes mellitus—Epirubicin—liver cancer	0.000221	0.0106	CcSEcCtD
Acetylsalicylic acid—Vascular purpura—Epirubicin—liver cancer	0.000215	0.0103	CcSEcCtD
Acetylsalicylic acid—Diabetes mellitus—Doxorubicin—liver cancer	0.000205	0.00979	CcSEcCtD
Acetylsalicylic acid—Urticaria—Sorafenib—liver cancer	0.000203	0.00973	CcSEcCtD
Acetylsalicylic acid—Renal impairment—Epirubicin—liver cancer	0.000202	0.00967	CcSEcCtD
Acetylsalicylic acid—Purpura—Epirubicin—liver cancer	0.0002	0.00955	CcSEcCtD
Acetylsalicylic acid—Vascular purpura—Doxorubicin—liver cancer	0.000199	0.00952	CcSEcCtD
Acetylsalicylic acid—Hypoglycaemia—Epirubicin—liver cancer	0.000197	0.00943	CcSEcCtD
Acetylsalicylic acid—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000192	0.00921	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Sorafenib—liver cancer	0.000189	0.00902	CcSEcCtD
Acetylsalicylic acid—Renal impairment—Doxorubicin—liver cancer	0.000187	0.00895	CcSEcCtD
Acetylsalicylic acid—Purpura—Doxorubicin—liver cancer	0.000185	0.00884	CcSEcCtD
Acetylsalicylic acid—Hypoglycaemia—Doxorubicin—liver cancer	0.000182	0.00873	CcSEcCtD
Acetylsalicylic acid—Pruritus—Sorafenib—liver cancer	0.000181	0.00866	CcSEcCtD
Acetylsalicylic acid—ABCB1—liver—liver cancer	0.000179	0.00474	CbGeAlD
Acetylsalicylic acid—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000178	0.00852	CcSEcCtD
Acetylsalicylic acid—Hypokalaemia—Epirubicin—liver cancer	0.000175	0.00838	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Sorafenib—liver cancer	0.000175	0.00838	CcSEcCtD
Acetylsalicylic acid—Dizziness—Sorafenib—liver cancer	0.000169	0.0081	CcSEcCtD
Acetylsalicylic acid—Asthma—Epirubicin—liver cancer	0.000166	0.00796	CcSEcCtD
Acetylsalicylic acid—Influenza—Epirubicin—liver cancer	0.000166	0.00796	CcSEcCtD
Acetylsalicylic acid—Vomiting—Sorafenib—liver cancer	0.000163	0.00779	CcSEcCtD
Acetylsalicylic acid—Hypokalaemia—Doxorubicin—liver cancer	0.000162	0.00775	CcSEcCtD
Acetylsalicylic acid—Rash—Sorafenib—liver cancer	0.000161	0.00772	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Sorafenib—liver cancer	0.000161	0.00771	CcSEcCtD
Acetylsalicylic acid—Influenza—Doxorubicin—liver cancer	0.000154	0.00736	CcSEcCtD
Acetylsalicylic acid—Asthma—Doxorubicin—liver cancer	0.000154	0.00736	CcSEcCtD
Acetylsalicylic acid—Nausea—Sorafenib—liver cancer	0.000152	0.00727	CcSEcCtD
Acetylsalicylic acid—Drowsiness—Epirubicin—liver cancer	0.000148	0.00709	CcSEcCtD
Acetylsalicylic acid—Sweating—Epirubicin—liver cancer	0.000142	0.0068	CcSEcCtD
Acetylsalicylic acid—Drowsiness—Doxorubicin—liver cancer	0.000137	0.00656	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Epirubicin—liver cancer	0.000134	0.0064	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Epirubicin—liver cancer	0.000133	0.00637	CcSEcCtD
Acetylsalicylic acid—Sweating—Doxorubicin—liver cancer	0.000132	0.00629	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Epirubicin—liver cancer	0.000124	0.00594	CcSEcCtD
Acetylsalicylic acid—Haemoglobin—Doxorubicin—liver cancer	0.000124	0.00592	CcSEcCtD
Acetylsalicylic acid—Flushing—Epirubicin—liver cancer	0.000124	0.00591	CcSEcCtD
Acetylsalicylic acid—Haemorrhage—Doxorubicin—liver cancer	0.000123	0.00589	CcSEcCtD
Acetylsalicylic acid—Tinnitus—Doxorubicin—liver cancer	0.000115	0.00549	CcSEcCtD
Acetylsalicylic acid—Flushing—Doxorubicin—liver cancer	0.000114	0.00547	CcSEcCtD
Acetylsalicylic acid—Anaemia—Epirubicin—liver cancer	0.000107	0.00512	CcSEcCtD
Acetylsalicylic acid—Agitation—Epirubicin—liver cancer	0.000106	0.0051	CcSEcCtD
Acetylsalicylic acid—Vertigo—Epirubicin—liver cancer	0.000104	0.00498	CcSEcCtD
Acetylsalicylic acid—Syncope—Epirubicin—liver cancer	0.000104	0.00497	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Epirubicin—liver cancer	0.000104	0.00496	CcSEcCtD
Acetylsalicylic acid—Loss of consciousness—Epirubicin—liver cancer	0.000102	0.00487	CcSEcCtD
Acetylsalicylic acid—Convulsion—Epirubicin—liver cancer	0.0001	0.0048	CcSEcCtD
Acetylsalicylic acid—Hypertension—Epirubicin—liver cancer	0.0001	0.00479	CcSEcCtD
Acetylsalicylic acid—Anaemia—Doxorubicin—liver cancer	9.91e-05	0.00474	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Epirubicin—liver cancer	9.87e-05	0.00472	CcSEcCtD
Acetylsalicylic acid—Chest pain—Epirubicin—liver cancer	9.87e-05	0.00472	CcSEcCtD
Acetylsalicylic acid—Agitation—Doxorubicin—liver cancer	9.85e-05	0.00471	CcSEcCtD
Acetylsalicylic acid—Vertigo—Doxorubicin—liver cancer	9.63e-05	0.00461	CcSEcCtD
Acetylsalicylic acid—Syncope—Doxorubicin—liver cancer	9.62e-05	0.0046	CcSEcCtD
Acetylsalicylic acid—Leukopenia—Doxorubicin—liver cancer	9.6e-05	0.00459	CcSEcCtD
Acetylsalicylic acid—Confusional state—Epirubicin—liver cancer	9.54e-05	0.00456	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Epirubicin—liver cancer	9.46e-05	0.00453	CcSEcCtD
Acetylsalicylic acid—Loss of consciousness—Doxorubicin—liver cancer	9.42e-05	0.00451	CcSEcCtD
Acetylsalicylic acid—Shock—Epirubicin—liver cancer	9.31e-05	0.00445	CcSEcCtD
Acetylsalicylic acid—Convulsion—Doxorubicin—liver cancer	9.29e-05	0.00444	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Epirubicin—liver cancer	9.26e-05	0.00443	CcSEcCtD
Acetylsalicylic acid—Hypertension—Doxorubicin—liver cancer	9.26e-05	0.00443	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Epirubicin—liver cancer	9.23e-05	0.00442	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Epirubicin—liver cancer	9.14e-05	0.00437	CcSEcCtD
Acetylsalicylic acid—Chest pain—Doxorubicin—liver cancer	9.13e-05	0.00437	CcSEcCtD
Acetylsalicylic acid—Arthralgia—Doxorubicin—liver cancer	9.13e-05	0.00437	CcSEcCtD
Acetylsalicylic acid—Confusional state—Doxorubicin—liver cancer	8.82e-05	0.00422	CcSEcCtD
Acetylsalicylic acid—Anaphylactic shock—Doxorubicin—liver cancer	8.75e-05	0.00419	CcSEcCtD
Acetylsalicylic acid—Shock—Doxorubicin—liver cancer	8.61e-05	0.00412	CcSEcCtD
Acetylsalicylic acid—Thrombocytopenia—Doxorubicin—liver cancer	8.57e-05	0.0041	CcSEcCtD
Acetylsalicylic acid—Tachycardia—Doxorubicin—liver cancer	8.54e-05	0.00409	CcSEcCtD
Acetylsalicylic acid—Hyperhidrosis—Doxorubicin—liver cancer	8.46e-05	0.00405	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Epirubicin—liver cancer	8.43e-05	0.00403	CcSEcCtD
Acetylsalicylic acid—Somnolence—Epirubicin—liver cancer	8.41e-05	0.00402	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Epirubicin—liver cancer	8.33e-05	0.00398	CcSEcCtD
Acetylsalicylic acid—Dyspnoea—Doxorubicin—liver cancer	7.8e-05	0.00373	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Epirubicin—liver cancer	7.79e-05	0.00373	CcSEcCtD
Acetylsalicylic acid—Somnolence—Doxorubicin—liver cancer	7.78e-05	0.00372	CcSEcCtD
Acetylsalicylic acid—Dyspepsia—Doxorubicin—liver cancer	7.7e-05	0.00369	CcSEcCtD
Acetylsalicylic acid—Urticaria—Epirubicin—liver cancer	7.51e-05	0.00359	CcSEcCtD
Acetylsalicylic acid—Feeling abnormal—Doxorubicin—liver cancer	7.21e-05	0.00345	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Epirubicin—liver cancer	6.97e-05	0.00333	CcSEcCtD
Acetylsalicylic acid—Urticaria—Doxorubicin—liver cancer	6.95e-05	0.00333	CcSEcCtD
Acetylsalicylic acid—Pruritus—Epirubicin—liver cancer	6.69e-05	0.0032	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Epirubicin—liver cancer	6.47e-05	0.0031	CcSEcCtD
Acetylsalicylic acid—Hypersensitivity—Doxorubicin—liver cancer	6.45e-05	0.00308	CcSEcCtD
Acetylsalicylic acid—Dizziness—Epirubicin—liver cancer	6.25e-05	0.00299	CcSEcCtD
Acetylsalicylic acid—Pruritus—Doxorubicin—liver cancer	6.19e-05	0.00296	CcSEcCtD
Acetylsalicylic acid—Vomiting—Epirubicin—liver cancer	6.01e-05	0.00288	CcSEcCtD
Acetylsalicylic acid—Diarrhoea—Doxorubicin—liver cancer	5.99e-05	0.00286	CcSEcCtD
Acetylsalicylic acid—Rash—Epirubicin—liver cancer	5.96e-05	0.00285	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Epirubicin—liver cancer	5.96e-05	0.00285	CcSEcCtD
Acetylsalicylic acid—Dizziness—Doxorubicin—liver cancer	5.79e-05	0.00277	CcSEcCtD
Acetylsalicylic acid—Nausea—Epirubicin—liver cancer	5.62e-05	0.00269	CcSEcCtD
Acetylsalicylic acid—Vomiting—Doxorubicin—liver cancer	5.56e-05	0.00266	CcSEcCtD
Acetylsalicylic acid—Rash—Doxorubicin—liver cancer	5.52e-05	0.00264	CcSEcCtD
Acetylsalicylic acid—Dermatitis—Doxorubicin—liver cancer	5.51e-05	0.00264	CcSEcCtD
Acetylsalicylic acid—Nausea—Doxorubicin—liver cancer	5.2e-05	0.00249	CcSEcCtD
Acetylsalicylic acid—ALB—Hemostasis—PIK3CB—liver cancer	5.13e-06	2.38e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—PIK3CA—liver cancer	5.12e-06	2.38e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—STAT3—liver cancer	5.12e-06	2.38e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—STAT3—liver cancer	5.12e-06	2.38e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—TERT—liver cancer	5.1e-06	2.37e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Immune System—AKT1—liver cancer	5.1e-06	2.37e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—MTOR—liver cancer	5.09e-06	2.36e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—PIK3CB—liver cancer	5.09e-06	2.36e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—MTHFR—liver cancer	5.03e-06	2.34e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—IL6—liver cancer	4.99e-06	2.32e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.99e-06	2.32e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	4.96e-06	2.3e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PPARA—liver cancer	4.94e-06	2.29e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—HRAS—liver cancer	4.93e-06	2.29e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—GSTP1—liver cancer	4.92e-06	2.28e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—KRAS—liver cancer	4.91e-06	2.28e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	4.88e-06	2.27e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—KRAS—liver cancer	4.86e-06	2.26e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—CYP2E1—liver cancer	4.85e-06	2.25e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—HMOX1—liver cancer	4.85e-06	2.25e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—HPGDS—liver cancer	4.84e-06	2.25e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—CYP2E1—liver cancer	4.83e-06	2.24e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.82e-06	2.24e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.81e-06	2.23e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CDKN1B—liver cancer	4.78e-06	2.22e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—MTHFR—liver cancer	4.77e-06	2.22e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—TERT—liver cancer	4.76e-06	2.21e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—MYC—liver cancer	4.75e-06	2.21e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—MYC—liver cancer	4.75e-06	2.21e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.75e-06	2.21e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—TGFB1—liver cancer	4.74e-06	2.2e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—TGFB1—liver cancer	4.74e-06	2.2e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PSMA4—liver cancer	4.74e-06	2.2e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PSMD10—liver cancer	4.74e-06	2.2e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—HRAS—liver cancer	4.73e-06	2.2e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—IL6—liver cancer	4.72e-06	2.19e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—IL2—liver cancer	4.71e-06	2.19e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.7e-06	2.18e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—IL2—liver cancer	4.68e-06	2.17e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.67e-06	2.17e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—KDR—liver cancer	4.66e-06	2.17e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MAPK14—liver cancer	4.63e-06	2.15e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PSMD10—liver cancer	4.62e-06	2.15e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PSMA4—liver cancer	4.62e-06	2.15e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GOT2—liver cancer	4.61e-06	2.14e-05	CbGpPWpGaD
Acetylsalicylic acid—AKR1C1—Signaling Pathways—AKT1—liver cancer	4.61e-06	2.14e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	4.55e-06	2.11e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—JUN—liver cancer	4.55e-06	2.11e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—ESR1—liver cancer	4.54e-06	2.11e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—CYCS—liver cancer	4.54e-06	2.11e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—GSTM1—liver cancer	4.52e-06	2.1e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—CYCS—liver cancer	4.51e-06	2.1e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CTNNB1—liver cancer	4.51e-06	2.1e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—PIK3CA—liver cancer	4.51e-06	2.1e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GOT2—liver cancer	4.5e-06	2.09e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—F2—liver cancer	4.49e-06	2.08e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—PIK3CA—liver cancer	4.46e-06	2.07e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GOT1—liver cancer	4.46e-06	2.07e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GGT1—liver cancer	4.46e-06	2.07e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.43e-06	2.06e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GGT1—liver cancer	4.43e-06	2.06e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GOT1—liver cancer	4.43e-06	2.06e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—CDKN1A—liver cancer	4.41e-06	2.05e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	4.41e-06	2.05e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—KRAS—liver cancer	4.39e-06	2.04e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—KRAS—liver cancer	4.39e-06	2.04e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.39e-06	2.04e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—TP53—liver cancer	4.37e-06	2.03e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Innate Immune System—AKT1—liver cancer	4.35e-06	2.02e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—CYP2E1—liver cancer	4.33e-06	2.01e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.33e-06	2.01e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PSMD10—liver cancer	4.32e-06	2.01e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PSMA4—liver cancer	4.32e-06	2.01e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—MAPK8—liver cancer	4.3e-06	2e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—PIK3CG—liver cancer	4.3e-06	1.99e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—APC—liver cancer	4.3e-06	1.99e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—CYP1A1—liver cancer	4.28e-06	1.99e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PIK3CG—liver cancer	4.23e-06	1.96e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—CYP2E1—liver cancer	4.23e-06	1.96e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GOT2—liver cancer	4.2e-06	1.95e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.19e-06	1.95e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Adaptive Immune System—AKT1—liver cancer	4.18e-06	1.94e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—HRAS—liver cancer	4.18e-06	1.94e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—HRAS—liver cancer	4.13e-06	1.92e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PPARG—liver cancer	4.08e-06	1.89e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—CYCS—liver cancer	4.05e-06	1.88e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—BRAF—liver cancer	4.04e-06	1.88e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—PIK3CA—liver cancer	4.03e-06	1.87e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—PIK3CA—liver cancer	4.03e-06	1.87e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—APC—liver cancer	4.01e-06	1.86e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—VEGFA—liver cancer	4.01e-06	1.86e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GSTP1—liver cancer	4e-06	1.86e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—IL6—liver cancer	4e-06	1.86e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—MTHFR—liver cancer	3.99e-06	1.86e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	3.99e-06	1.85e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GSTP1—liver cancer	3.98e-06	1.85e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GOT1—liver cancer	3.98e-06	1.85e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GGT1—liver cancer	3.98e-06	1.85e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—CYCS—liver cancer	3.96e-06	1.84e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—IL6—liver cancer	3.95e-06	1.83e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—CYP2E1—liver cancer	3.95e-06	1.83e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—HMOX1—liver cancer	3.95e-06	1.83e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—STAT3—liver cancer	3.93e-06	1.83e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—HMOX1—liver cancer	3.92e-06	1.82e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PPARA—liver cancer	3.92e-06	1.82e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—TP53—liver cancer	3.9e-06	1.81e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—TP53—liver cancer	3.9e-06	1.81e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GOT1—liver cancer	3.88e-06	1.8e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GGT1—liver cancer	3.88e-06	1.8e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.82e-06	1.78e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—PIK3CD—liver cancer	3.78e-06	1.75e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—BRAF—liver cancer	3.77e-06	1.75e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—SERPINE1—liver cancer	3.74e-06	1.73e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—HRAS—liver cancer	3.73e-06	1.73e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—HRAS—liver cancer	3.73e-06	1.73e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PIK3CD—liver cancer	3.72e-06	1.73e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—CYCS—liver cancer	3.7e-06	1.72e-05	CbGpPWpGaD
Acetylsalicylic acid—NFKBIA—Signaling Pathways—AKT1—liver cancer	3.69e-06	1.71e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—GSTM1—liver cancer	3.68e-06	1.71e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—TGFB1—liver cancer	3.68e-06	1.71e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—ALB—liver cancer	3.67e-06	1.7e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—GSTM1—liver cancer	3.66e-06	1.7e-05	CbGpPWpGaD
Acetylsalicylic acid—TP53—Signaling Pathways—AKT1—liver cancer	3.64e-06	1.69e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GGT1—liver cancer	3.63e-06	1.68e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GOT1—liver cancer	3.63e-06	1.68e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—IL6—liver cancer	3.57e-06	1.66e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—IL6—liver cancer	3.57e-06	1.66e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GSTP1—liver cancer	3.57e-06	1.66e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—PIK3CD—liver cancer	3.52e-06	1.64e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—HMOX1—liver cancer	3.52e-06	1.64e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.52e-06	1.63e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GSTP1—liver cancer	3.49e-06	1.62e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—CYP1A1—liver cancer	3.49e-06	1.62e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—SERPINE1—liver cancer	3.48e-06	1.62e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—CYP1A1—liver cancer	3.47e-06	1.61e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—HMOX1—liver cancer	3.44e-06	1.6e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—KRAS—liver cancer	3.4e-06	1.58e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—KRAS—liver cancer	3.38e-06	1.57e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—RAF1—liver cancer	3.37e-06	1.57e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PIK3CG—liver cancer	3.36e-06	1.56e-05	CbGpPWpGaD
Acetylsalicylic acid—RPS6KA3—Signaling Pathways—AKT1—liver cancer	3.3e-06	1.53e-05	CbGpPWpGaD
Acetylsalicylic acid—EDNRA—Signaling Pathways—AKT1—liver cancer	3.3e-06	1.53e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MTOR—liver cancer	3.29e-06	1.53e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—PIK3CB—liver cancer	3.29e-06	1.53e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—GSTM1—liver cancer	3.28e-06	1.52e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GSTP1—liver cancer	3.26e-06	1.51e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—MTHFR—liver cancer	3.25e-06	1.51e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PIK3CB—liver cancer	3.24e-06	1.5e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PPARG—liver cancer	3.24e-06	1.5e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—MTHFR—liver cancer	3.23e-06	1.5e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—HMOX1—liver cancer	3.21e-06	1.49e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—GSTM1—liver cancer	3.2e-06	1.49e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PPARA—liver cancer	3.19e-06	1.48e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PPARA—liver cancer	3.17e-06	1.47e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—RAF1—liver cancer	3.15e-06	1.46e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—PIK3CA—liver cancer	3.13e-06	1.45e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—CYP1A1—liver cancer	3.11e-06	1.45e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—PIK3CA—liver cancer	3.1e-06	1.44e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CDKN1B—liver cancer	3.09e-06	1.43e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—MTOR—liver cancer	3.07e-06	1.43e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—PIK3CB—liver cancer	3.07e-06	1.43e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—CYP1A1—liver cancer	3.04e-06	1.41e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CASP3—liver cancer	3.03e-06	1.41e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—TP53—liver cancer	3.03e-06	1.41e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—IL2—liver cancer	3.02e-06	1.4e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—GSTM1—liver cancer	2.99e-06	1.39e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PIK3CD—liver cancer	2.95e-06	1.37e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CCND1—liver cancer	2.95e-06	1.37e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—JUN—liver cancer	2.94e-06	1.37e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CTNNB1—liver cancer	2.92e-06	1.36e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—ALB—liver cancer	2.91e-06	1.35e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—MTHFR—liver cancer	2.9e-06	1.35e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—HRAS—liver cancer	2.89e-06	1.34e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—CDKN1B—liver cancer	2.88e-06	1.34e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—HRAS—liver cancer	2.87e-06	1.33e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.86e-06	1.33e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MMP9—liver cancer	2.86e-06	1.33e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—CDKN1A—liver cancer	2.85e-06	1.32e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.85e-06	1.32e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PPARA—liver cancer	2.85e-06	1.32e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—CYP1A1—liver cancer	2.84e-06	1.32e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—MTHFR—liver cancer	2.83e-06	1.31e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MAPK8—liver cancer	2.78e-06	1.29e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PPARA—liver cancer	2.78e-06	1.29e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—IL6—liver cancer	2.75e-06	1.28e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PIK3CG—liver cancer	2.73e-06	1.27e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—CTNNB1—liver cancer	2.72e-06	1.26e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PIK3CG—liver cancer	2.72e-06	1.26e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—CDKN1A—liver cancer	2.66e-06	1.24e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—MTHFR—liver cancer	2.65e-06	1.23e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PPARG—liver cancer	2.64e-06	1.22e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PPARG—liver cancer	2.62e-06	1.22e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PPARA—liver cancer	2.6e-06	1.21e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PIK3CB—liver cancer	2.57e-06	1.19e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—VEGFA—liver cancer	2.57e-06	1.19e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.56e-06	1.19e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Hemostasis—AKT1—liver cancer	2.56e-06	1.19e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—STAT3—liver cancer	2.54e-06	1.18e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Immune System—AKT1—liver cancer	2.54e-06	1.18e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PIK3CG—liver cancer	2.44e-06	1.13e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PIK3CD—liver cancer	2.4e-06	1.11e-05	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PIK3CD—liver cancer	2.39e-06	1.11e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PIK3CG—liver cancer	2.38e-06	1.1e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—STAT3—liver cancer	2.37e-06	1.1e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—ALB—liver cancer	2.37e-06	1.1e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—MYC—liver cancer	2.36e-06	1.1e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—TGFB1—liver cancer	2.36e-06	1.1e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PPARG—liver cancer	2.35e-06	1.09e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.33e-06	1.08e-05	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PPARG—liver cancer	2.3e-06	1.07e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PIK3CG—liver cancer	2.22e-06	1.03e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—MYC—liver cancer	2.21e-06	1.02e-05	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—TGFB1—liver cancer	2.2e-06	1.02e-05	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—KRAS—liver cancer	2.18e-06	1.01e-05	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PPARG—liver cancer	2.15e-06	9.96e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PIK3CD—liver cancer	2.14e-06	9.95e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—ALB—liver cancer	2.12e-06	9.82e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PIK3CB—liver cancer	2.09e-06	9.72e-06	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PIK3CD—liver cancer	2.09e-06	9.71e-06	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PIK3CB—liver cancer	2.08e-06	9.66e-06	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—ALB—liver cancer	2.06e-06	9.59e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—KRAS—liver cancer	2.04e-06	9.46e-06	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—PIK3CA—liver cancer	2.01e-06	9.32e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—PIK3CA—liver cancer	1.97e-06	9.17e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PIK3CD—liver cancer	1.95e-06	9.07e-06	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—TP53—liver cancer	1.94e-06	9.01e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—ALB—liver cancer	1.93e-06	8.96e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—PIK3CA—liver cancer	1.87e-06	8.69e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PIK3CB—liver cancer	1.87e-06	8.67e-06	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—HRAS—liver cancer	1.86e-06	8.62e-06	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PIK3CB—liver cancer	1.82e-06	8.47e-06	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—IL6—liver cancer	1.78e-06	8.25e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—HRAS—liver cancer	1.73e-06	8.04e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PIK3CB—liver cancer	1.7e-06	7.91e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—IL6—liver cancer	1.66e-06	7.7e-06	CbGpPWpGaD
Acetylsalicylic acid—IKBKB—Signaling Pathways—AKT1—liver cancer	1.64e-06	7.61e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS1—Metabolism—AKT1—liver cancer	1.61e-06	7.49e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—PIK3CA—liver cancer	1.57e-06	7.28e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Disease—AKT1—liver cancer	1.53e-06	7.1e-06	CbGpPWpGaD
Acetylsalicylic acid—PTGS2—Metabolism—AKT1—liver cancer	1.28e-06	5.95e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—PIK3CA—liver cancer	1.28e-06	5.92e-06	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—PIK3CA—liver cancer	1.27e-06	5.89e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—PIK3CA—liver cancer	1.14e-06	5.29e-06	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—PIK3CA—liver cancer	1.11e-06	5.16e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C8—Metabolism—AKT1—liver cancer	1.04e-06	4.84e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—PIK3CA—liver cancer	1.04e-06	4.82e-06	CbGpPWpGaD
Acetylsalicylic acid—ALB—Metabolism—AKT1—liver cancer	1.04e-06	4.81e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C19—Metabolism—AKT1—liver cancer	9.3e-07	4.32e-06	CbGpPWpGaD
Acetylsalicylic acid—ABCB1—Metabolism—AKT1—liver cancer	9.08e-07	4.22e-06	CbGpPWpGaD
Acetylsalicylic acid—CYP2C9—Metabolism—AKT1—liver cancer	8.48e-07	3.94e-06	CbGpPWpGaD
